RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Jean Nicolas Vauthey,Giuseppe Zimmitti,Scott Kopetz,Junichi Shindoh,Su S. Chen,Andreas Andreou,Steven A. Curley,Thomas A. Aloia,Dipen M. Maru +8 more
Reads0
Chats0
TLDR
RAS mutation predicts early lung recurrence and worse survival after curative resection of CLM and this information may be used to individualize systemic and local tumor-directed therapies and follow-up strategies.Abstract:
Objective:To determine the impact of RAS mutation status on survival and patterns of recurrence in patients undergoing curative resection of colorectal liver metastases (CLM) after preoperative modern chemotherapy.Background:RAS mutation has been reported to be associated with aggressive tumor bioloread more
Citations
More filters
Journal ArticleDOI
Colorectal cancer liver metastases – a population-based study on incidence, management and survival
TL;DR: The worse survival in liver metastatic right-sided Colon cancer could possibly be explained by the higher number of metastases, as well as more extensive segmental involvement compared with left-sided colon and rectal cancer, even though the latter had a higher incidence of liver metastases.
Journal ArticleDOI
Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus.
René Adam,Aimery de Gramont,Joan Figueras,Norihiro Kokudo,Francis Kunstlinger,Evelyne M. Loyer,Graeme J. Poston,Philippe Rougier,Laura Rubbia-Brandt,Alberto Sobrero,Catherine Teh,Sabine Tejpar,Eric Van Cutsem,Jean Nicolas Vauthey,Lars Påhlman +14 more
TL;DR: The consensus was for chemotherapy before surgery in most cases, and all patients with synchronous CRCLM should be evaluated by a hepatobiliary multidisciplinary team.
Journal ArticleDOI
The Tumor Burden Score: A New "Metro-ticket" Prognostic Tool For Colorectal Liver Metastases Based on Tumor Size and Number of Tumors.
Kazunari Sasaki,Daisuke Morioka,Simone Conci,Georgios A. Margonis,Yu Sawada,Andrea Ruzzenente,Takafumi Kumamoto,Calogero Iacono,Nikolaos Andreatos,Alfredo Guglielmi,Itaru Endo,Timothy M. Pawlik +11 more
TL;DR: TBS may be an accurate tool to account for the impact of tumor morphology on long-term survival among patients undergoing resection of CRLM and had excellent prognostic discriminatory power.
Journal ArticleDOI
Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases
Kristoffer Watten Brudvik,Scott Kopetz,Liang Li,Claudius Conrad,Thomas A. Aloia,J.N. Vauthey +5 more
TL;DR: A meta‐analysis was undertaken to clarify the impact of KRAS mutation on outcomes in patients with resectable CLM, irrespective of treatment with chemotherapy or anti‐EGFR therapy.
Journal ArticleDOI
RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases
Kristoffer Watten Brudvik,Kristoffer Watten Brudvik,Robert P. Jones,Felice Giuliante,Junichi Shindoh,Junichi Shindoh,Guillaume Passot,Michael H. Chung,Juhee Song,Liang Li,Vegar J. Dagenborg,Åsmund Avdem Fretland,Bård I. Røsok,Agostino Maria De Rose,Francesco Ardito,Bjørn Edwin,Elena Panettieri,Luigi Maria Larocca,Suguru Yamashita,Claudius Conrad,Thomas A. Aloia,Graeme J. Poston,Bjørn Atle Bjørnbeth,Jean Nicolas Vauthey +23 more
TL;DR: The m-CS is a simple validated tool that predicts survival after resection of CLM because it accurately stratified patients by overall and recurrence-free survival in both the initial patient series and validation cohort, whereas the t-CS did not.
References
More filters
Journal ArticleDOI
Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.
TL;DR: The new complication classification appears reliable and may represent a compelling tool for quality assessment in surgery in all parts of the world.
Journal ArticleDOI
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Eric Van Cutsem,Claus Henning Köhne,Erika Hitre,J. Zaluski,Chung Rong Chang Chien,A. Makhson,Geert R. D'Haens,Tamás Pintér,Robert Lim,György Bodoky,Jae Kyung Roh,Gunnar Folprecht,Paul Ruff,Christopher Stroh,Sabine Tejpar,Michael Schlichting,Johannes Nippgen,Philippe Rougier +17 more
TL;DR: In this paper, the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer was investigated.
Journal ArticleDOI
Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer: Analysis of 1001 Consecutive Cases
TL;DR: There is a need for clearly defined and widely applicable clinical criteria for the selection of patients who may benefit from hepatic resection for metastatic colorectal cancer and studies of preoperative staging techniques or of adjuvant therapies should consider using such a score for stratification of patients.
Journal ArticleDOI
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock,Bart Claes,David Bernasconi,Jef De Schutter,Bart Biesmans,George Fountzilas,Konstantine T. Kalogeras,Vassiliki Kotoula,Demetris Papamichael,Pierre Laurent-Puig,Frédérique Penault-Llorca,Philippe Rougier,Bruno Vincenzi,Daniele Santini,Giuseppe Tonini,Federico Cappuzzo,Milo Frattini,Francesca Molinari,Piercarlo Saletti,Sara De Dosso,Miriam Martini,Alberto Bardelli,Salvatore Siena,Andrea Sartore-Bianchi,Josep Tabernero,Teresa Macarulla,Frédéric Di Fiore,Alice Gangloff,Fortunato Ciardiello,Per Pfeiffer,Camilla Qvortrup,Tine Plato Hansen,Eric Van Cutsem,Hubert Piessevaux,Diether Lambrechts,Mauro Delorenzi,Mauro Delorenzi,Sabine Tejpar +37 more
TL;DR: This is the largest cohort to date of patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab plus chemotherapy in the pre-KRAS selection era and confirmed that, if KRAS is not mutated, assessing BRAF, NRAS, and PIK3CA population response rates confirmed that.
Journal ArticleDOI
Surgical resection of colorectal carcinoma metastases to the liver : A prognostic scoring system to improve case selection, based on 1568 patients
Nordlinger B,Marguerite Guiguet,Jean-Christophe Vaillant,P. Balladur,Karim Boudjema,Philippe Bachellier,Daniel Jaeck +6 more
TL;DR: Five‐year survival rates after resection of liver metastases from colorectal carcinoma are close to 25%, and selection of patients likely to benefit from surgery remains controversial and subjective.
Related Papers (5)
Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
Jean-Yves Douillard,Kelly S. Oliner,Salvatore Siena,Josep Tabernero,Ronald Burkes,Mario Edmundo Barugel,Yves Humblet,György Bodoky,David Cunningham,Jacek Jassem,Fernando Rivera,Ilona Kocáková,Paul Ruff,Maria Blasinska-Morawiec,Martin Šmakal,Jean-Luc Canon,Mark Rother,Richard Thomas Williams,Alan Rong,Jeffrey Wiezorek,Roger Sidhu,Scott D. Patterson +21 more